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Objective
To characterize Tregs and to determine the serum levels of regulatory cytokines in patients with BP.
Methods
In BP lesional skin, immunohistochemistry and confocal microscopy were performed for CD4 
Results
The frequency of FOXP3 + cells was significantly reduced in skin lesions from patients with BP (P < 0.001) compared with psoriasis and AD. Moreover, the number of IL-10 + cells was lower in BP than in psoriasis (P < 0.001) and AD (P = 0.002), while no differences were observed in the number of TGF-β 
Introduction
Regulatory T cells (Tregs) represent a subset of immune effector cells, firstly described by Sakaguchi et al., [1] which play a central role in immune homeostasis by regulating the maintenance of self-tolerance and are therefore essential for the control of immune responses. [2] [3] [4] Currently, distinct subsets of Tregs have been described, [2] subdivided on the basis of different expression of cell surface markers, production of cytokines and mechanism of action. [5] Naturally occurring thymic-derived CD4 + CD25 + Tregs (nTregs) represent 1-10% of total CD4 + T cells in thymus, peripheral blood and lymphoid tissues, and acquire their regulatory capacity during normal thymopoiesis. Phenotypically, nTregs are characterized by the bright expression of CD25 and by the constitutive expression of specific markers, such as the transcription factor forkhead box P3 (FOXP3), [4] the glucocorticoid-induced tumour-necrosis factor receptor-related protein and the cytotoxic T-lymphocyte associated antigen 4. Another group of CD4 + CD25 + Tregs is represented by the 'antigen induced or adaptive' Tregs (aTregs). The suppressive function of these induced Tregs is mediated by the production of the suppressive cytokines interleukin (IL)-10 and transforming growth factor (TGF)-β.
Recent literature proposed that a lack of Tregs number or a defect in function could potentially lead to loss of tolerance and thus to the development of autoimmunity. Indeed, numerous autoimmune and immune-mediated diseases (including gastritis, thyroiditis, type 1 diabetes, myastenia gravis, rheumatoid arthritis and multiple sclerosis) have been shown to present significant depletion in the number and/or function impairment of Tregs. [2-4, 6, 7] A significant down-modulation of Tregs was found also in different immune-mediated dermatoses, such as psoriasis, scleroderma, dermatomyositis, lupus erythematosus and graft-versus-host disease. [8] [9] [10] [11] [12] To date, only a few studies focused on Tregs in autoimmune bullous skin diseases, a group including different clinical-pathological entities characterized by the development of autoimmunity against structural components maintaining cell-cell (pemphigus group) and cell-matrix [bullous pemphigoid (BP) group] adhesion. In particular, BP, the most common autoimmune blistering disease, is characterized by the development of auto-antibodies directed against components of the hemidesmosome adhesion complex, the BP230 and collagen XVII/BP180 proteins. Although the underlying mechanisms involved in triggering the autoimmune response in BP are not wellunderstood, BP is now considered a T-cell dependent autoimmune disease with the presence of CD4 + autoreactive T cells that recognize the ectodomain of BP180. [13] [14] [15] The pathogenesis of the disease involves also other factors, including complement activation, mast cell degranulation, accumulation of inflammatory cells (eosinophils, neutrophils) and the release of proteases. [13, [16] [17] [18] Although Tregs pathway seems to be impaired in pemphigus vulgaris, [19] [20] [21] [22] contrasting results are reported for BP. In fact, while Rensing-Ehl et al. did not find differences between BP patients and healthy controls, [23] more recently a study by Arakawa and co-workers [24] and a study from our research group [25] demonstrated a reduction in Tregs numbers in the skin and in the blood of BP patients respectively.
In this study, to confirm our previous results and to analyse further the role of Tregs in the pathogenesis of BP, the expression and distribution of both naturally-occurring FOXP3 + Tregs and 'antigen-induced' IL-10 and TGF-β producing Tregs, have been investigated using immunohistochemistry, confocal microscopy, flow-cytometry and ELISA both in the lesional skin and in the blood of patients with BP.
Materials and methods

Patients
A total of 21 patients with BP (9 M, 12 F; median age 68 years, range 39-84) were included into the study. The diagnosis of BP was made on the basis of a typical clinical presentation of classic BP with diffuse blistering of the skin, subepidermal blistering with granulocytic infiltrate at the histopathology, linear immunoglobulin G (IgG) and complement three deposits along the basement membrane zone at the direct immunofluorescence examination, linear IgG deposits at the blister roof of sodium chloride split human skin at the indirect immunofluorescence, and presence of circulating anti-BP180 antibodies by ELISA.
Skin biopsy specimens and blood samples from patients with psoriasis (n = 10, 4 M, 6 F; median age 44 years, range 26-61) and atopic dermatitis (AD) (n = 10; 5 M, 5 F, median age 38 years, range 22-59) were used as controls, along with skin and blood samples from 30 age-and gendermatched healthy controls (HC). The patients and controls were recruited from two Italian Dermatologic Clinics (Florence and Turin) belonging to the Italian Group for Cutaneous Immunopathology.
All patients and controls underwent a skin biopsy and a peripheral blood test during the first visit and before any topical and/or systemic treatment was started. Furthermore, a blood sample was collected from 11 BP patients at the end of consolidation phase as defined by Murrell et al. [26] Table 1 shows the therapy regimens and the time needed to achieve the end of consolidation phase for each BP patient included into the study. The trial was approved by the medical ethical committee of each Hospital and was conducted according to the Declaration of Helsinki. All the patients and controls provided written informed consent to participate to the study.
Immunohistochemistry
The expression of different Tregs markers was analysed in serial sections of lesional skin biopsy specimens of 15 BP patients, 10 psoriasis patients, 10 AD patients, as well as in healthy skin of eight HC using single immunohistochemical staining as described previously. [27] Skin specimens, that had been immediately frozen at −80 °C in liquid nitrogen, were cut into 5-μm thick sections and stained immunohistochemically. The monoclonal antibodies included those to CD4 ( 
Confocal microscopy
About 10-μm serial sections of fresh frozen skin biopsies from eight patients with BP, five with psoriasis, five with AD and five HC were fixed with ice cold acetone then blocked with 0.25% casein in Tris-buffered saline (TBS; 0.88% NaCl, ThermoFisher, 0.24% tris(hydroxymethyl) aminomethane, (VWR International) and distilled water). Primary antibodies against human CD4 (mouse IgG2b, OKT4, 1 : 50, BioLegend, San Diego, CA, USA) and FOXP3 (mouse IgG1, 206D, 1 : 50, BioLegend) were prepared in TBS containing 1% FCS and incubated on sections for 1 h at room temperature. Secondary antibodies against mouse isotypes IgG2a DyLight 488 (poly24092, BioLegend) and IgG2b AlexaFluor 555 (Molecular Probes, Grand Island, NY, USA) at 1 : 200 each were prepared and incubated on sections for 1 h Sections were visualized with Nikon C2 confocal microscope (Nikon, Tokyo, Japan).
Flow cytometric analysis
The flow cytometric analysis was performed at a single site (Turin). Peripheral blood lymphocyte samples from 21 BP patients before therapy and 11 BP patients (number 1, 3, 4, 5, 6, 7, 8, 12, 13, 17, 19; see Table 1 ) after therapy were evaluated according to their immunofluorescence reactivity, using FACSCalibur or FACSCanto™ II cytometer and analysed with CellQuest or FACSDiva software (Becton Dickinson, San Jose, CA, USA). Surface markers on blood were performed by four or six-colour immunofluorescence analyses, using simultaneously antibodies conjugated to FITC, PE, PerCP or PerCP Cy5.5, Pe-Cy7, allophycocyanin (APC) and APC-H7. At least 10 000 lymphocytes were collected for each antibody combination. Lymphocyte purity was verified by the standard forward and sideways scattering parameters, by means of a CD45 gating analysis. A wide panel of mAbs directed against T-cell antigens was routinely tested to screen patients' phenotypes. The following mAbs were analysed for this study: anti-CD4 PerCP or Pe-Cy7 (clone SK3, mouse IgG1) from (BD Biosciences, San Jose, CA, USA) anti-CD25 PE, or APC (clone CD25-3G10, cells. FOXP3 cytometric expression was analysed using mononuclear cells purified from peripheral blood using Lymphoprep (1.077 g/mL; Axis-Shield Poc As, Oslo, Norway) density gradient centrifugation. Firstly, the cells were incubated with surface antibodies, anti-CD4 PerCP or PE-Cy7 and anti-CD25 APC for 10 min at room temperature. They were then stained with anti-FOXP3 PE (clone PCH101, rat IgG2a; eBiosciences, San Diego, CA, USA), according to the manufacturer's protocol, using fixation and permeabilization buffers from the same provider. compartment. Blood samples of 10 patients with psoriasis, 10 with AD and 30 HC were investigated as controls; data of the patients with psoriasis and AD were retrieved from our previous study, where the same methods were used. [10] Enzyme-linked immunosorbent assay
As for flow cytometric assay, even the ELISA was performed at a single site (Florence). Blood samples from 21 BP patients were collected at the diagnosis and after the resolution of the disease and were centrifuged for 20 min at 10000 g (5417R microcentrifuge; Eppendorf, Hamburg, Germany). Then, serum samples were subdivided into small aliquots to be stored at −80°C until tested for cytokine levels. Solid phase ELISA kits (R&D Systems, Minneapolis, MN, USA) were used to determine TGF-β1 and IL-10 serum levels, according to the manufacturers' instructions. Samples and standards were analysed in duplicates and only variation coefficients <15% were accepted. As control, serum samples of 10 HC were analysed.
Statistical analysis
The results are presented as medians [25th-75th percentile]. The Mann-Whitney U-test was used to compare the number of Tregs in peripheral blood of patients and healthy controls and the results of the immunohistochemical and confocal microscopy analysis. Both the Kruskal-Wallis with Dunn post hoc test and the Student's t-test were used to compare the data from the ELISA analysis, giving similar results. The results of flow cytometric analysis and ELISA in BP patients before and after treatment were paired and analysed using Wilcoxon signed rank test. The correlation between the percentages of circulating Tregs with IL-10 serum levels in BP patients after treatment was calculated by Spearman's test. Results were considered significant with a P value <0.05. The level of CD4 + cell infiltration was similar in patients with BP, psoriasis and AD. HC showed significantly lower numbers of CD4 + infiltrating cells than BP and control diseases (HC vs. BP, psoriasis and AD: P < 0.001) (Fig. 1) . In contrast, the frequency of CD25 + cells was significantly lower in BP skin lesions compared with psoriasis (P = 0.008) and AD (P = 0.01), and higher compared with HC (P < 0.001) (Fig. 2) . In BP inflammatory infiltrate, few FOXP3 + cells were identified within the superficial dermis (Fig. 1) . In contrast, patients with psoriasis and AD revealed a significantly higher number of FOXP3 + cells in the infiltrate (BP vs. psoriasis: P < 0.001; BP vs. AD: P = 0.001) (Fig. 2) . No differences could be found in the absolute number of FOXP3-expressing cells between BP patients and HC (Fig. 2) .
Results
CD4
The binding of FOXP3 antibody could be blocked by preincubating the antibody with specific FOXP3 peptide in skin specimens. For control purposes, an isotype-matched control antibody was used and consistently yielded negative results. The frequency of FOXP3 + cells, expressed as the percentage of CD4 + cells, was found to be significantly lower in BP specimens compared with HC (P = 0.009), psoriasis (P < 0.001) and AD (P < 0.001) (Fig. 2) . (Table 2) Several TGF-β + cells preferentially located in the superficial dermis (Fig. 1) were detected in BP, without statistical differences compared with psoriasis and AD (Fig. 2) . In contrast, HC showed a reduced number of TGF-β + if compared with BP (P < 0.001), psoriasis (P < 0.001) and AD (P < 0.001). Finally, TGF-β + /CD4 + cell ratio was similar in BP, HC, psoriasis and AD skin specimens.
Only few IL-10 + cells were found in the superficial dermis of BP skin lesions (Fig. 1) . Their number was similar to that found in HC, but significantly lower than in patients with psoriasis (P < 0.001) or AD (P = 0.02) (Fig. 2) . Furthermore, IL-10 + /CD4 + cell ratio was lower in BP skin lesions than in HC (P < 0.001), in AD (P = 0.003) and in psoriasis (P < 0.001).
Peripheral blood Tregs quantification (Figure 3)
The presence of CD25 bright FOXP3 + within the CD4 + circulating compartment was analysed in BP and compared with HC, psoriasis and AD patients (Fig. 3a) . The dot plot of a representative BP patient is reported in Fig. 3b . + subset in BP patients were also slightly lower than those of patients with both psoriasis and AD (median: 2.5% and 2.6% respectively), even if this difference was not significant (P = 0.07).
The analysis of the circulating Tregs kinetics after treatment was available only in 11 patients. Interestingly, in these cases, the resolution of the skin lesions was associated with a parallel increase in the percentages of the CD25 (Fig. 4) .
Figure 4.
Serum levels of the regulatory cytokines TGF-β and IL-10 in patients with bullous pemphigoid before and after therapy and in healthy controls. BP-pre, bullous pemphigoid before therapy; BP-post, bullous pemphigoid after therapy; HC, healthy controls; *P < 0.05. No significant differences in IL-10 concentrations were found between patients with BP before treatment (median [25th-75th percentile]: 8.9 pg/mL [4.3-15.7] ) and HC (median [25th-75th percentile]: 15.2 pg/mL [14.4-17.5] ). However, after therapy and thus after the resolution of the disease, BP patients showed significantly higher IL-10 serum levels than before therapy (median [25th-75th percentile]: 24.5 pg/mL [17.7-31.2] ; P = 0.01) (Fig. 4) . Interestingly, in treated patients, IL-10 serum levels showed a statistically significant correlation with the percentage of CD4 
Discussion
This study was designed to characterize the expression of both naturally-occurring and antigeninduced Tregs in skin biopsies and blood samples from patients with BP, to evaluate their potential role in the pathogenesis of the disease. Our main finding was the demonstration of a significant reduction in Tregs in patients with BP compared with HC. Interestingly, our data showed that the decreased frequency of FOXP3 + Tregs was simultaneously present both in the skin and peripheral blood of patients with BP. According to a recent study by our research group, [25] this finding suggests that the reduction in Tregs observed in the blood was not the result of a preferential homing of these cells into the skin, or vice versa, but rather it reflects their real downregulation, and therefore, their potential impaired suppressive function that could play a role in the pathogenesis of the disease.
Our results are in contrast with those by Rensing-Ehl et al., [23] who did not find differences in the number of circulating Tregs between BP patients and HC. In their study, however, the analysis of circulating Tregs was made only the basis of the CD25 In contrast, we did not find any significant differences in the serum levels of both TGF-β and IL-10 between patients with BP and HC. In agreement with our data, several studies from the literature demonstrated that, while IL-10 seems to be elevated in the blister fluid of patients with BP, its serum concentration overlaps that of healthy subjects. [31] [32] [33] However, after the resolution of the disease, BP patients showed higher IL-10 serum levels than before treatment. These findings might imply a relative lack of IL-10 in BP patients, where the levels of this cytokine, overlapping those of HC, could not be able to ensure an adequate immunoregulation in a state of enhanced reactivity such as BP. After steroid therapy which, as discussed above, is able to enhance Tregs numbers and function, IL-10 concentrations augmented consequently and reached levels that could be able to balance the autoimmune response present in BP patients. Accordingly, Teraki et al. demonstrated that corticosteroids may control inflammatory responses in BP by promoting expansion of IL-10-producing cells. [34] Interestingly, we also found a positive correlation between IL-10 serum levels and circulating Treg percentages in BP patients after treatment, suggesting that they are strictly related.
IL-10 is a potent antiinflammatory cytokine that is able to suppress production of both type 1 and type 2 cytokines. [35] A number of studies have shown beneficial effects of IL-10 in different models of cell-mediated autoimmunity, [36, 37] including a model of BP. [38] Moreover, IL-10 is able to potentiate the IL-4-induced synthesis of IgG4, [39] a IgG subclass that is less pathogenic than IgG1 in patients with BP, as it is not capable of fixing complement. [40] Thus, taken as a whole, these data suggest that IL-10 could represent a therapeutic approach for the management of BP. [34] Our study, however, has some limitations, including the fact that FOXP3, although still considered the most specific marker for Tregs, can be transiently expressed on activated T cells. Further studies including functional assays and the use of other markers for Tregs, such as CD127low and CD39high, [41] would augment the specificity of the results.
To conclude, despite such limitations, our findings suggested a reduction in both skin-homing and circulating FOXP3 + Tregs in patients with BP, together with a downregulation of the IL-10 pathway. The resolution of the disease after a course with systemic corticosteroids was paralleled by an increase in circulating Tregs and of IL-10 serum levels, suggesting a possible alternative way of action of these drugs other than affecting T effector cells.
